Navigation Links
/C O R R E C T I O N -- Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee/
Date:7/21/2008

In the news release, "Update on the SEAS Study" issued on 21 Jul 2008 07:00 GMT, by Prof Terje Pedersen,SEAS Study Principal Investigator & Head of Steering Committee over PR Newswire, we are advised by a representative of the organisation that the following information has been added to the release:

Satellite coordinates, audio access and URL for webcast:

Satellite:

European Satellite:

AB1 12.5 Deg West

Txp: B6 Lower, Channel 2

DL: 11152.700 V

symbol rate 5.632

FEC 3/4

American Satellite

Domsat:

Galaxy 11 @ 91 degrees west

KU Band: Txp 13, Channel A

DL: 11946.5 H

SYMBOL RATE 5.632

FEC 3/4

Audio access details are as follows:

Telephone number: 0044-207-190-1232

Conference Title: SEAS Study UpDate

Conference ID: 3904345

Please note that the URL to access the live Webcast has changed from: http://clients.mediaondemand.net/pedersen/live.asx to: http://clients.mediaondemand.net/pedersen
Complete, corrected release follows:

Update on the SEAS Study

Satellite coordinates and URL for webcast:

Satellite:

European Satellite:

AB1 12.5 Deg West

Txp: B6 Lower, Channel 2

DL: 11152.700 V

symbol rate 5.632

FEC 3/4

American Satellite

Domsat:

Galaxy 11 @ 91 degrees west

KU Band: Txp 13, Channel A

DL: 11946.5 H

SYMBOL RATE 5.632

FEC 3/4

Audio access details are as follows:

Telephone number: 0044-207-190-1232

Conference Title: SEAS Study UpDate

Conference ID: 3904345

To access the live Webcast please go to: http://clients.mediaondemand.net/pedersen

Professor Terje Pedersen (Ulleval University Hospital, Oslo, Norway), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study, will provide an update on the study on Monday the 21st July.

Also present in London will be Sir Richard Peto (Professor of Medical Statistics and Epidemiology and Co-director of the Clinical Trials Service Unit, University of Oxford) Professor Rory Collins (BHF Professor of Medicine and Epidemiology at the University of Oxford and Co-director of the Clinical Trials Service Unit) and Professor Ingar Holme, PhD, (Professor of Biostatistics, University of Oslo and Ulleval University Hospital, Oslo, Norway), SEAS steering committee statistician.

The London panel will be joined by Professor Eugene Braunwald (Professor of Medicine at Harvard Medical School) who will participate via Web link from Boston and Professor Robert M Califf (Professor of Medicine, Head of Duke Clinical Research, Duke University) available via phone link.
You are invited to join us at:

The Hilton London Metropole Hotel,

King Suite (3rd Floor, West Wing),

225 Edgware Road, London W2 1JU

When: 21st July at 5.30pm for a 6pm start, BST There will be a Q&A session after the press announcement. The Q&A session is only available for members of the media.

Prof Terje Pedersen, SEAS Study Principal Investigator & Head of Steering Committee

------

Update on the SEAS Study

LONDON, July 21 /PRNewswire/ -- Professor Terje Pedersen (Ulleval University Hospital, Oslo, Norway), lead investigator for the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) Study, will provide an update on the study on Monday the 21st July.

Also present in London will be Sir Richard Peto (Professor of Medical Statistics and Epidemiology and Co-director of the Clinical Trials Service Unit, University of Oxford) Professor Rory Collins (BHF Professor of Medicine and Epidemiology at the University of Oxford and Co-director of the Clinical Trials Service Unit) and Professor Ingar Holme, PhD, (Professor of Biostatistics, University of Oslo and Ulleval University Hospital, Oslo, Norway), SEAS steering committee statistician.

The London panel will be joined by Professor Eugene Braunwald (Professor of Medicine at Harvard Medical School) who will participate via Web link from Boston and Professor Robert M Califf (Professor of Medicine, Head of Duke Clinical Research, Duke University) available via phone link.
You are invited to join us at:

The Hilton London Metropole Hotel,

King Suite (3rd Floor, West Wing),

225 Edgware Road, London W2 1JU

When: 21st July at 5.30pm for a 6pm start, BST

OR

The press conference will be Webcast live, and archived, available at:

http://clients.mediaondemand.net/pedersen/live.asx

http://clients.mediaondemand.net/pedersen/archive.asx Additionally the press conference can be accessed via satellite and full coordinates for USA and Europe will be issued by 1pm BST.

There will be a Q&A session after the press announcement. The Q&A session is only available for members of the media.


'/>"/>
SOURCE ;
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
5. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
6. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
7. Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD
8. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
9. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
10. MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus
11. Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... HILL, N.C. , June 24, 2016 /PRNewswire/ ... healthcare decisions and regulators/payers have placed more emphasis ... new environment, patient support programs in the pharmaceutical ... for patients, medications. Consequently, pharmaceutical companies are focusing ... ensure they are providing products and services that ...
(Date:6/24/2016)... , June 24, 2016  Global Blood Therapeutics, ... company developing novel therapeutics for the treatment of ... announced the closing of its previously announced underwritten ... at the public offering price of $18.75 per ... were offered by GBT. GBT estimates net proceeds ...
(Date:6/24/2016)... 24, 2016 ... the addition of the " Global Markets for ... This report focuses on ... updated review, including its applications in various applications. The ... which includes three main industries: pharmaceutical and biotechnology, food ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... 25, 2016 , ... Austin residents seeking Mohs surgery services, can now turn ... to Dr. Russell Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization ... selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin ... injury. Recently, he has implemented orthobiologic procedures as a method for treating his ... of the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... June ... about the dangers associated with chronic pain and the benefits of holistic treatments, ... individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is ...
(Date:6/24/2016)... ... 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited to ... Recovery® program to drive cancer patients to and from their cancer treatments. Comfort ... quality of life and ongoing independence. Getting to and from medical treatments is ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® & Innovative Solutions today ... cultivation and processing operations at its production facility, and opened its first two ... the manufacturer of a complete system of proactive air and surface purification solutions ...
Breaking Medicine News(10 mins):